(Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin, is now off-patent in India, paving the way for domestic drugmakers to launch generic versions.

When a manufacturer creates a new medication, the company applies for a product patent, which gives them ownership over the product for 20 years. For those two decades, it is prohibited by law for ...

nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished ...

They hope that training thousands of employees on generative AI will boost productivity in drug development. This article is part of "AI in Action," a series exploring how companies are ...

The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange Book tees up a pharmaceutical-industry push for the Supreme Court to weigh in ...

Rappler lists key events involving the ICC and Duterte’s war on drugs. We will update this timeline as new information ... he could also be a suspect. This development, however, only becomes ...

or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, today announced the filing of a new patent with ... scientists with drug development and global product ...

Countries like India and Brazil which had reached high levels of indigenisation began to have their battles with drug ... development. Each chapter deals with one aspect of patents and leads ...

Jindal served as governor of Louisiana and as a U.S. assistant secretary of Health and Human Services. Katebi is deputy director of the Center for a Healthy America at the America First Policy ...